Brucellosis is caused by Gram negative, facultative intracellular bacteria of the
Brucella genus.
Brucella melitensis Rev-1, an attenuated smooth strain used to control
B. melitensis infection gives heterologous protection against other
Brucella spp. and is currently considered as the best vaccine for the prophylaxis of caprine brucellosis (
1). However, due to some problems related to attenuated
B. melitensis Rev1 (
2,
3), subunit vaccine protective against
B. melitensis is desirable.
Escherichia coli is frequently used for production of recombinant proteins because of the extensive knowledge available about this organism for both physiology and genetic characterization (
4). The subsequent downstream purification of products from
E. coli, remains noticeably more difficult compared to secreted proteins from eukaryotic expression organisms. Since the production of protein by
E. coli in most manufacturing processes is performed intracellularly, the protein product must be selectively separated from the host proteins (
5).
Proteins with up to 95% purity still contain a significant amount of endotoxins. Endotoxins are lipopolysaccharides (LPS) associated with the outer membrane of Gram-negative bacteria. The inherent toxicity of these LPSs has a profound effect on biochemical events of certain cells and can interfere with in vitro experiments (
6).
The threshold level of endotoxin for intravenous applications is set to 5 endotoxin units (EU) per kg body weight and hour by all pharmacopoeias (7). Because of this toxicity, the removal of even minute amounts is essential for safe administration or biological cell-based application. The following study introduces a method using of Ni-NTA agarose for recombinant protein purification by which the simultaneous removal of endotoxins is made possible.